Cost-utility analyses of targeted immunomodulators in rheumatoid arthritis: systematic review

References

• Wasserstein R. George Box: a model statistician. Significance. 2010;7(3):134–135.
   Google Scholar
• Hunter TM, Boytsov NN, Zhang X, et al. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. Rheumatol Int. 2017;37(9):1551–1557.
   PubMed Web of Science ®Google Scholar
• Dadoun S, Zeboulon-Ktorza N, Combescure C, et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine. 2013;80(1):29–33. Epub 2012 Mar 27. Review.
   PubMed Web of Science ®Google Scholar
• Abdel-Nasser AM, Rasker JJ, Vaikenburg HA. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Semin Arthritis Rheum. 1997;27(2):123–140.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos A, Finckh A, Huizinga T, et al. Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK. Pharmacoeconomics. 2014;32(8):775–787.
   PubMed Web of Science ®Google Scholar
• Boyadzieva VV, Stoilov N, Stoilov RM, et al. Quality of life and cost study of rheumatoid arthritis therapy with biological medicines. Front Pharmacol. 2018;9:794.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015;11(5):276–289.
   PubMed Web of Science ®Google Scholar
• Joensuu JT, Huoponen S, Aaltonen KJ, et al. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS One. 2015;10(3):e0119683.
   PubMed Web of Science ®Google Scholar
• Alemao E, Al MJ, Boonen AA, et al. Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLoS One. 2018;13(10):e0205013.
   PubMed Web of Science ®Google Scholar
• FDA Approved Drugs for Rheumatology | Centerwatch. [cited 2019 May 29]. Available from: https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/19/rheumatology.
   Google Scholar
• National Institute for Health and Care Excellence 2017. Baricitinib for moderate to severe rheumatoid arthritis (NICE technology appraisal guideance TA 466); [cited 2019 May 29]. Available from: https://www.nice.org.uk/guidance/ta466/
   Google Scholar
• National Institute for Health and Care Excellence 2017. Sarilumab for moderate to severe rheumatoid arthritis (NICE technology appraisal guideance TA 485). [cited 2019 May 29]. Available from: https://www.nice.org.uk/guidance/ta485/
   Google Scholar
• National Institute for Health and Care Excellence 2017. Tofacitinib for moderate to severe rheumatoid arthritis (NICE technology appraisal guideance TA 480). [cited 2019 May 29]. Available from: https://www.nice.org.uk/guidance/ta480/
   Google Scholar
• Carlson JJ, Ogale S, Dejonckheere F, et al. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis. Value Health. 2015;18(2):173–179.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Incerti D, Mutebi A, et al. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. J Med Econ. 2017;20(7):703–714.
   PubMed Web of Science ®Google Scholar
• Tzanetakos C, Tzioufas A, Goules A, et al. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece. Rheumatol Int. 2017;37(9):1441–1452.
   PubMed Web of Science ®Google Scholar
• Hidalgo-Vega Á, Villoro R, Blasco JA, et al. Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain. Cost Eff Resour Alloc. 2015;13(1):11.
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, The PRISMA Group, et al. Preferred Reporting Items for Systematic Reviews and MetaAnalyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097.,
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) – explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231–250.
   PubMed Web of Science ®Google Scholar
• Wu B, Song Y, Leng L, et al. Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars. Clin Exp Rheumatol. 2015;33(1):20–26.
   PubMed Web of Science ®Google Scholar
• Alemao E, Johal S, Al MJ, et al. Cost-effectiveness analysis of abatacept compared with adalimumab on background methotrexate in biologic-naive adult patients with rheumatoid arthritis and poor prognosis. Value Health. 2018;21(2):193–202.
   PubMed Web of Science ®Google Scholar
• Stephens S, Botteman MF, Cifaldi MA, et al. Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease. BMJ Open. 2015;5(6):e006560–e006560.
   PubMed Web of Science ®Google Scholar
• Stevenson MD, Wailoo AJ, Tosh JC, et al. The cost-effectiveness of sequences of biological disease-modifying antirheumatic drug treatment in England for patients with rheumatoid arthritis who can tolerate methotrexate. J Rheumatol. 2017;44(7):973–980.
   PubMed Web of Science ®Google Scholar
• Bansback N, Phibbs CS, Sun H, et al. Triple therapy versus biologic therapy for active rheumatoid arthritis: a cost-effectiveness analysis. Ann Intern Med. 2017;167(1):8–16.
   PubMed Web of Science ®Google Scholar
• Claxton L, Taylor M, Gerber RA, et al. Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States. Curr Med Res Opin. 2018;34(11):1991–2000. Nov
   PubMed Web of Science ®Google Scholar
• Incerti D, Jansen JP. A description of the IVI-RA model. 2017 [updated October 2017]. Accessible from https://innovationvalueinitiative.github.io/IVI-RA/model-description/model-description.pdf
   Google Scholar
• Jalal H, O’Dell JR, Bridges SL, Jr, et al. Cost-effectiveness of triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(12):1751–1757.
   PubMed Web of Science ®Google Scholar
• Muszbek N, Proudfoot C, Fournier M, et al. Economic evaluation of sarilumab in the treatment of adult patients with moderately-to-severely active rheumatoid arthritis who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. Adv Ther. 2019;36(6):1337–1357.
   PubMed Web of Science ®Google Scholar
• Athanasakis K, Tarantilis F, Tsalapati K, et al. Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece. Rheumatol Int. 2015;35(9):1489–1495. Epub 2015 Mar 21.
   PubMed Web of Science ®Google Scholar
• Lee MY, Park SK, Park SY, et al. Cost-effectiveness of tofacitinib in the treatment of moderate to severe rheumatoid arthritis in South Korea. Clin Ther. 2015;37(8):1662–1676.e2.
   PubMed Web of Science ®Google Scholar
• Park SK, Park SH, Lee MY, et al. Cost-effectiveness analysis of treatment sequence initiating with etanercept compared with leflunomide in rheumatoid arthritis: impact of reduced etanercept cost with patent expiration in South Korea. Clin Ther. 2016;38(11):2430–2446.e3.
   PubMedGoogle Scholar
• Valle-Mercado C, Cubides MF, Parra-Torrado M, et al. Cost-effectiveness of biological therapy compared with methotrexate in the treatment for rheumatoid arthritis in Colombia. Rheumatol Int. 2013;33(12):2993–2997.
   PubMed Web of Science ®Google Scholar
• Gissel C, Götz G, Repp H. Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany. Z Rheumatol. 2016;75(10):1006–1015. Dec
   PubMed Web of Science ®Google Scholar
• Hashemi-Meshkini A, Nikfar S, Glaser E, et al. Cost-effectiveness analysis of tocilizumab in comparison with infliximab in Iranian rheumatoid arthritis patients with inadequate response to tDMARDs: a multistage Markov model. Value Health Reg Issues. 2016;9:42–48.
   PubMedGoogle Scholar
• Quartuccio L, di Bidino R, Ruggeri M, et al. Cost-effectiveness analysis of two rituximab retreatment regimens for longstanding rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015;67(7):947–955.
   PubMed Web of Science ®Google Scholar
• Tran-Duy A, Boonen A, Kievit W, et al. Modelling outcomes of complex treatment strategies following a clinical guideline for treatment decisions in patients with rheumatoid arthritis. Pharmacoeconomics. 2014;32(10):1015–1028.
   PubMed Web of Science ®Google Scholar
• Kvamme MK, Lie E, Uhlig T, et al. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies. Rheumatology (Oxford). 2015;54(7):1226–1235.
   PubMed Web of Science ®Google Scholar
• Kostić M, Jovanović S, Tomović M, et al. Cost-effectiveness analysis of tocilizumab in combination with methotrexate for rheumatoid arthritis: a Markov model based on data from Serbia, country in socioeconomic transition. Vojnosanit Pregl. 2014;71(2):144–148. Feb
   PubMed Web of Science ®Google Scholar
• Stevenson M, Archer R, Tosh J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess. 2016;20(35):1–610.
   Web of Science ®Google Scholar
• Bermejo I, Stevenson M, Archer R, et al. Certolizumab pegol for treating rheumatoid arthritis following inadequate response to a TNF-α inhibitor: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2017;35(11):1141–1151.
   PubMed Web of Science ®Google Scholar
• Fournier M, Chen CI, Kuznik A, et al. Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient. CEOR. 2019;11:117–128.
   Google Scholar
• Rheumatoid Arthritis: Final Report – ICER. [updated 2017 April 7; cited 2019 May 29]. Accessible from: https://icer-review.org/material/ra-final-report/
   Google Scholar
• Chen DY, Hsu PN, Tang CH, et al. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan. J Med Econ. 2019;13:1–11.
   Google Scholar
• Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43(3):203–220.
   PubMed Web of Science ®Google Scholar
• Hernández Alava M, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health. 2012;15(3):550–561.
   PubMed Web of Science ®Google Scholar
• Hernández Alava M, Wailoo AJ, Wolfe F, et al. The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. Rheumatology. 2013;52(5):944–950.
   PubMed Web of Science ®Google Scholar
• Shafrin J, Hou N, Tebeka MG, et al. Economic burden of rheumatoid arthritis is higher for ACPA-positive patients. Paper presented at: 2016 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; 2016 November 11–16, Abstract 2229; Washington, DC.
   Google Scholar
• Wei W, Knapp K, Wang L, et al. Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: real-world observational study of rheumatoid arthritis patients in the United States with prior tumor necrosis factor inhibitor therapy. Adv Ther. 2017;34(8):1936–1952.
   PubMed Web of Science ®Google Scholar
• Wailoo AJ, Bansback N, Brennan A, et al. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum. 2008;58(4):939–946.
   PubMedGoogle Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations of the second panel on cost-effectiveness in health and medicine. JAMA. 2016; 316(10):1093–1103.
   PubMed Web of Science ®Google Scholar